CLAIMS

1. Use of an agent that induces or promotes the expression and/or activity of neuronal nitric oxide synthase (nNOS) in one or more ocular cells in the manufacture of a medicament for treating or preventing myopia, or for inhibiting the development of myopia.

2. The use according to claim 1, wherein the ocular cells express nNOS or are part of an nNOS producing structure in the eye.

3. The use according to claim 1 or claim 2, wherein the ocular cells are amacrine cells.

4. The use according to any one of claims 1 to 3, wherein the agent is L-arginine.

5. The use according to any one of claims 1 to 4, wherein the agent is to be administered directly to an eye of the subject.

6. The use according to claim 5, wherein said administration comprises intravitreal, conjunctival or scleral administration or administration to the retina.

7. The use according to claim 6, wherein the administration is via intravitreal, conjunctival or scleral injection of an intravitreal, conjunctival or scleral implant.

8. The use according to any one of claims 1 to 5, wherein the agent is to be administered orally or topically.

9. The use according to any one of claims 1 to 8, wherein the myopia is lens- or instrument-induced myopia, simple myopia, early or late-onset myopia, progressive myopia, degenerative myopia or pathological myopia.

10. The use according to any one of claims 1 to 9, wherein the treatment, prevention or inhibition of development of myopia comprises inhibiting or preventing the progression of myopia in a myopic eye; reversing established myopia; or

inhibiting or preventing the development of myopia in an eye predisposed thereto or at risk of developing myopia.